BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 30, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Protagonist Therapeutics patents new SLC40A1 ligands
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Hematologic
Protagonist Therapeutics patents new SLC40A1 ligands
Oct. 26, 2022
No Comments
Protagonist Therapeutics Inc. has disclosed hepcidin mimetic conjugates acting as solute carrier family 40 member 1 (SLC40A1, ferroportin) ligands with extended half-life and stability.
BioWorld Science
Hematologic
Patents